STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #264 by analyst upside · 2026-06-27
QNRX
Quoin Pharmaceuticals, Ltd.
Healthcare · Market Cap $9M · P/E 0x
ANALYST PRICE TARGET
+380.9%
implied upside to consensus target
Current Price $4.45
Consensus Target $21.4
Bull Target $35.0
Bear Target $12.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
2
Hold
0
Sell
1
52-Week Low $3.25
52-Week High $41.8
YTD Return -68.4%
FUNDAMENTALS
Market Cap $9M
P/E Ratio (TTM) N/A
Forward P/E -1.5x
EPS (TTM) $-10.07
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.25
52-Week High $41.8
Current Price $4.45
Bear Target $12.0
Bull Target $35.0
● Now $4.45 ● Target $21.4
TRADING DATA
Avg Volume 240K
YTD Return -68.4%
Analyst Count 5
Consensus Buy
Upside to Target +380.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Quoin Pharmaceuticals, Ltd. (QNRX) is currently trading at $4.45 with a Wall Street consensus price target of $21.4, implying potential upside of 380.9% over the next 12 months. 5 analysts currently cover QNRX, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $35.0, while the most cautious has a target of $12.0.

QNRX operates in the Healthcare sector with a market capitalisation of $9M. The stock is down 68.4% year-to-date and is currently trading near the lower end of its 52-week range of $3.25 – $41.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for QNRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

LUCID CAPITAL MARKETS ● Initiated
Buy 2026-05-04 40% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →